These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 30817045

  • 1. Comparison and cost analysis of three protocols for mobilization and apheresis of haematopoietic progenitor cells.
    López-Castaño F, Manresa P, Díaz V, Arranz E, López J, Pérez M, Alda O, Hernández L.
    J Clin Apher; 2019 Aug; 34(4):461-467. PubMed ID: 30817045
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost.
    Sohutskay DO, Tetrick AM, Goebel WS, Schwering D, Reddy MS.
    J Clin Apher; 2024 Oct; 39(5):e22145. PubMed ID: 39291715
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
    Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.
    Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
    Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S.
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
    [Abstract] [Full Text] [Related]

  • 8. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
    Ruano Camps R, Ortiz Pareja M, Vidales Mancha I, Muñoz Castillo IM, Heiniger Mazo AI.
    Farm Hosp; 2013 Jan; 37(4):317-21. PubMed ID: 24010693
    [Abstract] [Full Text] [Related]

  • 9. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S, Peter R, Wäscher D, Götze K, Verbeek M, Peschel C, Krackhardt AM.
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [Abstract] [Full Text] [Related]

  • 10. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF.
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
    Stover JT, Shaw JR, Kuchibhatla M, Horwitz ME, Engemann AM.
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
    [Abstract] [Full Text] [Related]

  • 12. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of three mobilization protocols for peripheral blood stem cell apheresis with Spectra Optia continuous mononuclear cell protocol in healthy dogs.
    Kim S, Hosoya K, Kobayashi A, Okumura M.
    Vet Comp Oncol; 2019 Mar; 17(1):61-68. PubMed ID: 30221450
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M, Silva M.
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.